Turning Point Therapeutics, Inc.

Clinical trials sponsored by Turning Point Therapeutics, Inc., explained in plain language.

Now part of Bristol-Myers Squibb Company BMY NYSE

A precision oncology company developing targeted therapies for cancer, acquired by Bristol-Myers Squibb.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New hope for kids with rare cancers: targeted drug repotrectinib enters trial Results expected Sep 2026 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 2 Not yet finished but already full! 1

New drug targets Hard-to-Treat cancers with MET mutations

Disease control Ongoing

This early-stage trial tests a new drug called TPX-0022 in adults with advanced lung, stomach, or other solid tumors that have specific MET gene changes. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors. About 95 participants will ta…

Phase 1 • Sponsor: Turning Point Therapeutics, Inc. • Aim: Disease control

Last updated Jun 27, 2026 07:52 UTC

Turning Point Therapeutics, Inc.

Upcoming readouts

New drug targets Hard-to-Treat cancers with MET mutations